Neuronetics (NASDAQ:STIM – Get Free Report) is set to issue its quarterly earnings data before the market opens on Monday, August 12th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Neuronetics Stock Down 4.8 %
Shares of STIM opened at $1.78 on Friday. The firm has a market capitalization of $53.40 million, a P/E ratio of -1.85 and a beta of 2.32. Neuronetics has a 12-month low of $1.03 and a 12-month high of $5.07. The company has a current ratio of 5.65, a quick ratio of 5.18 and a debt-to-equity ratio of 2.15. The firm has a fifty day moving average price of $1.87 and a 200-day moving average price of $2.92.
Analyst Upgrades and Downgrades
Separately, William Blair raised shares of Neuronetics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, May 14th.
Insider Buying and Selling
In other Neuronetics news, Director Robert Cascella acquired 50,000 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was bought at an average cost of $2.05 per share, with a total value of $102,500.00. Following the completion of the purchase, the director now directly owns 244,098 shares in the company, valued at $500,400.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Neuronetics news, Director Robert Cascella acquired 50,000 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was bought at an average cost of $2.05 per share, with a total value of $102,500.00. Following the completion of the purchase, the director now directly owns 244,098 shares in the company, valued at $500,400.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Keith J. Sullivan sold 24,162 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $1.90, for a total transaction of $45,907.80. Following the completion of the sale, the chief executive officer now directly owns 1,324,354 shares of the company’s stock, valued at $2,516,272.60. The disclosure for this sale can be found here. 9.80% of the stock is owned by insiders.
About Neuronetics
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
See Also
- Five stocks we like better than Neuronetics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 8/5 – 8/9
- P/E Ratio Calculation: How to Assess Stocks
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- 5 discounted opportunities for dividend growth investors
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.